Tempest Therapeutics Inc (TPST : NASDAQ)
Common Stock
$1.21
USD
+0.45 (60.18%)
Last updated: 2026-09-16
Get TPST alerts:
TPST
Tempest Therapeutics Inc
WealthAwesomePerformance
1 Day
+60.18%
1 Week
+33.11%
1 Month
+7.08%
YTD
-3.20%
Key Statistics
Market Cap
$20.01M
52W High
$12.23
52W Low
$0.74
P/E Ratio
-
50 Day MA
$0.99
200 Day MA
$1.88
Beta
-1.66
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/16/2026 | $1.07 | $1.48 | $0.97 | $1.21 | $1.21 | 101,567,710 |
| 9/15/2026 | $0.80 | $0.81 | $0.74 | $0.76 | $0.76 | 26,443,366 |
| 9/14/2026 | $0.80 | $0.82 | $0.75 | $0.78 | $0.78 | 143,423 |
| 9/11/2026 | $0.79 | $0.89 | $0.76 | $0.81 | $0.81 | 783,632 |
| 9/10/2026 | $0.95 | $0.95 | $0.80 | $0.80 | $0.80 | 391,000 |
| 9/9/2026 | $0.98 | $0.99 | $0.91 | $0.91 | $0.91 | 186,000 |
| 9/8/2026 | $1.02 | $1.03 | $0.98 | $0.99 | $0.99 | 199,600 |
| 9/4/2026 | $1.04 | $1.05 | $1.01 | $1.03 | $1.03 | 214,600 |
| 9/3/2026 | $1.10 | $1.10 | $1.04 | $1.05 | $1.05 | 181,900 |
| 9/2/2026 | $1.05 | $1.12 | $1.05 | $1.10 | $1.10 | 126,500 |
Analyst Price Targets
Based on 2 analysts covering TPST · as of Sep 17, 2026
Wall Street analysts forecast TPST stock price to rise 809.1% over the next 12 months.
Consensus
Hold3.00 / 5.00
Avg. Target
US$11.00
+809.1% Upside
Current Price
US$1.21
Last close
Analyst Breakdown (2 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TPST's historical volatility
30-Day Vol
169.1%
Annualized
90-Day Vol
126.0%
Annualized
Trend (90d)
-13.7%
Annualized drift
90d Mean
US$1.15
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$1.19 | US$0.66 – US$2.13 |
| 60 trading days | US$1.17 | US$0.51 – US$2.67 |
| 90 trading days | US$1.15 | US$0.42 – US$3.16 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-21.41M
- Profit Margin
- 0.00%
- ROE (TTM)
- -931.14%
- EPS (Diluted)
- -3.68
- Book Value
- 0.06
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About TPST.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| AMPGZ | Amplitech Group, Inc. Series B Right | $0.19 | +41.54% |